Unresectable Locally Advanced or Metastatic Solid Tumors Study
Phase: 2
Status: Ongoing
About
A Phase 2 Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Details
Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors (Cohorts for Prostate Cancer and Melanoma open)
Sponsor: Seagen Inc
NCT04032704
